Yoon‐Jong Bae

Hanmi Pharmaceutical (South Korea)

Papers

1

Total Citations

2

H-Index

1

About

Yoon‐Jong Bae is a leading urological researcher whose work focuses on improving prostate cancer (PCa) detection strategies, particularly through the use of 5-alpha reductase inhibitors (5ARIs) and prostate-specific antigen (PSA) testing. His major contributions include demonstrating that 5ARIs can enhance PCa detection by increasing opportunities for repeated PSA testing, a critical insight given the historically low PSA screening uptake among Korean men. This finding, published in a decade-long (2007–2016) nationwide observational study in Korea, has significant implications for clinical practice and public health policy. With 2 citations to date, this work is gaining recognition for its practical impact on early cancer detection. Bae’s research is notable for its large-scale, population-based approach, leveraging national health data to address real-world screening challenges. His work not only advances urological oncology but also highlights the importance of tailored screening protocols in diverse populations. For students and researchers, Bae’s studies offer a compelling example of how observational data can inform and improve cancer diagnostics, making his profile a valuable resource for those interested in prostate cancer epidemiology and preventive medicine.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
The Use of 5-Alpha Reductase Inhibitors Improves the Detection of Prostate Cancer by Increasing Opportunities for Repeated Prostate-Specific Antigen Testing: A Decade-Long (2007–2016) Nationwide Observational Study in Korea
2 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: Hanmi Pharmaceutical (South Korea)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago